GNPX Jun 2024 2.500 call
| Previous Close | 0.0200 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 2.50 |
| Expire Date | 2024-06-21 |
| Day's Range | 0.0200 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.27k |
PR NewswireGenprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of the Company's co-founder, President, Chairman and Chief Executive Officer (CEO), Rodney Varner, due to sudden complications after a courageous battle with cancer.
ACCESSWIRESidoti Events, LLC's Virtual May Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 8-9, 2024. The ...
PR NewswireGenprex to Present and Participate at Upcoming May Investor and Industry Conferences
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in May 2024.
